Skip to main content

Market Overview

Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development

Share:
Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development
  • Caladrius Biosciences Inc (NASDAQ: CLBShas received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.
  • The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.
  • Cassava Sciences Inc (NASDAQ: SAVAhas been awarded a new $2.7 million research grant award from the National Institutes of Health.
  • The grant will be used to fund its upcoming Phase 3 program with simufilam, its drug candidate for Alzheimer's disease.
  • Price Action: CLBS shares are trading 0.68% lower at $1.45, and SAVA shares are down 2.73% at $38.16 during the market session on the last check Wednesday.
 

Related Articles (CLBS + SAVA)

View Comments and Join the Discussion!

Posted-In: Alzheimer's diseaseBiotech News Penny Stocks Health Care Financing Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com